PMX 53

Drug Profile

PMX 53

Alternative Names: Hydrocinnamate analogues - Promics; PMX53

Latest Information Update: 09 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Peptech; The University of Queensland
  • Developer Arana Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Peptides
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Osteoarthritis
  • Discontinued Age-related macular degeneration; Burns; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 09 Mar 2011 No development reported - Preclinical for Osteoarthritis in Australia (PO)
  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
  • 19 Feb 2009 Discontinued - Phase-I for Age-related macular degeneration in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top